Sign in
TerminatedNo phase

The FibreGum Study - Changing the Course of Obesity in Children

Key facts

Who runs it
Insel Gruppe AG, University Hospital Bern
Where
Switzerland2 sites in 1 countryChoose a country to see its sites
Trial code
Status
Terminated
People taking part
93 people enrolled
Started
30 Nov 2022
Ended
23 Jan 2026
Type of study
Interventional, 3 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • FibreGum
  • Placebo
Record updated
18 February 2026
Why it stopped
Based on the Intention To Treat interim analysis results and the slow recruitment rate.

Who can take part

Age
10 years to 16 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 16 criteriaShow less

Who can take part

  • Informed Consent according to International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use/Good Clinical Practice (ICH/GCP) regulations prior to any study specific procedures
  • Obesity as determined by a BMI ≥97th percentile using the Swiss paediatric, age- and sex-matched growth charts
  • Newly referred within the last month to a tertiary weight management clinic
  • Participant willing to use the study specific monitoring app on his/her own or legal representatives' smartphone

Who cannot take part

  • Malignant disease on treatment or previous tumour affecting the appetite system (e.g., suprasellar, hypothalamic tumours)
  • Systemic antibiotic or anti-inflammatory medication (e.g. systemic intake of glucocorticoids) over the last 7 days
  • Participation in another investigation with an investigational drug within the 30 days preceding and during the present investigation
  • Congenital disorder affecting the cardiovascular, hepatic or respiratory system in a relevant way (as per PI's or specialist's evaluation)
  • Known eating disorder (medically diagnosed)
  • Inability to follow the procedures of the investigation, e.g. due to language problems, psychological disorders, etc. of the participant and/or legal representative
  • Antibiotic administration in the last 6 months
  • Pre- or probiotic treatment in the last 6 weeks
  • Any professionally supervised treatment for weight management within the last year
  • Consumption of more than one nicotine product per month (e.g. cigarette, gum)
  • Adolescent females: any stages of known pregnancy or lactation period
  • Dependency from the sponsor or the clinical investigator

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The aim of this study is thus to assess the effect of a chewing gum containing fibres on body weight, metabolism and the oral and intestinal microbiomes in a population of obese children.

The 3 groups in the trial

  • PlaceboPlacebo, for comparison

    Chewing gum containing maltitol powder

  • InvestigationalTreatment being tested

    chewing gums containing fibers

    Treatment: FibreGum

  • No-treatment controlNo study treatment, for comparison

    No study chewing gum

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
18 February 2026